Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like reviewing lab notebooks. CalciMedica’s 10-K spans pages of CRAC-channel biology, trial endpoints and burn-rate math that most investors simply don’t have time to decode. If you have ever wondered, “CalciMedica SEC filings explained simply,” this page was built to end the struggle.
Stock Titan’s AI distills every document the moment it hits EDGAR. Our platform delivers real-time updates on CalciMedica Form 4 insider transactions, surfaces R&D expense trends from each CalciMedica quarterly earnings report 10-Q filing, and flags pivotal study results buried in an 8-K. The same engine powers plain-English answers to questions investors routinely ask: How did cash runway shift this quarter? Which executives exercised options? What milestones were added to the risk-factor section?
Here’s what you can track today:
- CalciMedica annual report 10-K simplified—AI pulls pipeline timelines and liquidity tables in seconds.
- CalciMedica 8-K material events explained—immediate alerts on trial read-outs or financing news.
- CalciMedica executive stock transactions Form 4 with pattern recognition for insider buying.
- CalciMedica proxy statement executive compensation—see how pay aligns with clinical progress.
- CalciMedica earnings report filing analysis—compare quarter-over-quarter R&D spend effortlessly.
Whether you are understanding CalciMedica SEC documents with AI for the first time or fine-tuning a valuation model, our coverage of CalciMedica insider trading Form 4 transactions and every other filing type gives you the clarity you need—no scientific PhD required.
Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported transactions on this Form 4 dated 08/15/2025. The filing shows an acquisition of 5,076 shares of Common Stock at a weighted-average purchase price of $2.8977 per share (price range $2.80 to $2.90). The form also reports a disposition of 164,706 shares and multiple indirect holdings held through custodians and affiliated entities including FMTC Custodian, Oppenheimer & Co. Custodian, IRA Financial Trust Company, and several Valence Investments SPVs. The filing includes a note that detailed per-price share counts are available upon request.
CalciMedica, Inc. (CALC) reporting person Hebbar Sudarshan, the company's Chief Medical Officer, purchased additional common stock in two transactions. On 08/14/2025 he acquired 1,584 shares at a weighted average price of $2.585, bringing his direct beneficial ownership to 47,584 shares. On 08/15/2025 he acquired 4,392 shares at a weighted average price of $2.793, increasing his direct ownership to 51,976 shares. The filing was signed by an attorney-in-fact on 08/18/2025. The filing includes price ranges for the trades and notes that detailed per-price purchase counts are available on request.
CalciMedica, Inc. filed a Form 8-K reporting that on August 12, 2025 it issued a press release announcing financial results for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws.
The report is signed by CEO A. Rachel Leheny, Ph.D.. The filing confirms the Nasdaq ticker CALC and that the registrant identified itself as an emerging growth company.
FAQ
What is the current stock price of CALCIMEDICA (CALC)?
What is the market cap of CALCIMEDICA (CALC)?
